EP3740242C0 - LANGERIN+ CELL TARGETING - Google Patents
LANGERIN+ CELL TARGETINGInfo
- Publication number
- EP3740242C0 EP3740242C0 EP19700520.0A EP19700520A EP3740242C0 EP 3740242 C0 EP3740242 C0 EP 3740242C0 EP 19700520 A EP19700520 A EP 19700520A EP 3740242 C0 EP3740242 C0 EP 3740242C0
- Authority
- EP
- European Patent Office
- Prior art keywords
- langerin
- cell targeting
- targeting
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/36—Skin; Hair; Nails; Sebaceous glands; Cerumen; Epidermis; Epithelial cells; Keratinocytes; Langerhans cells; Ectodermal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/19—Dendritic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
- A61K40/24—Antigen-presenting cells [APC]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/46—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
- A61K47/6907—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a microemulsion, nanoemulsion or micelle
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
- A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54353—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals with ligand attached to the carrier via a chemical coupling agent
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Cell Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Hematology (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Zoology (AREA)
- Urology & Nephrology (AREA)
- Microbiology (AREA)
- Wood Science & Technology (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Virology (AREA)
- Dispersion Chemistry (AREA)
- Developmental Biology & Embryology (AREA)
- General Engineering & Computer Science (AREA)
- Toxicology (AREA)
- Dermatology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Nanotechnology (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18152362 | 2018-01-18 | ||
| EP18162955 | 2018-03-20 | ||
| PCT/EP2019/051055 WO2019141731A1 (en) | 2018-01-18 | 2019-01-16 | Langerin+ cell targeting |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| EP3740242A1 EP3740242A1 (en) | 2020-11-25 |
| EP3740242B1 EP3740242B1 (en) | 2025-06-18 |
| EP3740242C0 true EP3740242C0 (en) | 2025-06-18 |
| EP3740242B8 EP3740242B8 (en) | 2025-07-23 |
Family
ID=65019533
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP19700520.0A Active EP3740242B8 (en) | 2018-01-18 | 2019-01-16 | Langerin+ cell targeting |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US12290535B2 (en) |
| EP (1) | EP3740242B8 (en) |
| JP (1) | JP7566629B2 (en) |
| KR (1) | KR102492240B1 (en) |
| CN (1) | CN112074298B (en) |
| AU (1) | AU2019209502B2 (en) |
| BR (1) | BR112020014610A8 (en) |
| CA (1) | CA3088710C (en) |
| ES (1) | ES3037359T3 (en) |
| WO (1) | WO2019141731A1 (en) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4128253A4 (en) * | 2020-04-02 | 2023-09-13 | Exa Health, Inc. | Image-based analysis of a test kit |
| CN112386695B (en) * | 2020-11-30 | 2021-11-19 | 西安交通大学 | Chitosan-based nano prodrug carrying indocyanine green and platinum drugs and preparation method thereof |
| CN113416320B (en) * | 2021-06-28 | 2022-03-25 | 南京大学 | A degradable protein hydrogel based on the regulation of mechanical signals and its preparation method and application |
| US20250319024A1 (en) * | 2021-08-27 | 2025-10-16 | University Of Georgia Research Foundation, Inc. | Targeted nanoparticles and their uses related to infectious disease |
| JP2024022034A (en) * | 2022-08-05 | 2024-02-16 | 浜松ホトニクス株式会社 | A method for determining a region of a cell that has undergone programmed cell death, an apparatus including a determination unit, and an information processing program including a determination step |
| CA3268611A1 (en) * | 2022-10-14 | 2024-04-18 | Cutanos Gmbh | Lipid nanoparticle formulations for mrna delivery to langerhans cells |
| CN116178571B (en) * | 2023-02-21 | 2024-05-28 | 南开大学 | Endoplasmic reticulum-targeted artificial protein, recombinant saccharomyces cerevisiae, endoplasmic reticulum-targeted vesicle, immune adjuvant and vaccine |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8828477D0 (en) | 1988-12-06 | 1989-01-05 | Riker Laboratories Inc | Medical aerosol formulations |
| DK1761248T3 (en) | 2004-03-19 | 2012-09-03 | Rodos Biotarget Gmbh | Carbohydrate-derived liposomes destined to target cellular carbohydrate recognition domains of CTL / CTLD lecithins as well as intracellular delivery of therapeutically active compositions |
| AR078423A1 (en) | 2009-09-14 | 2011-11-09 | Baylor Res Inst | VACCINES DIRECTED TO LANGERHANS CELLS |
| US20120231023A1 (en) * | 2011-03-08 | 2012-09-13 | Baylor Research Institute | Novel Vaccine Adjuvants Based on Targeting Adjuvants to Antibodies Directly to Antigen-Presenting Cells |
| HUE043511T2 (en) | 2012-07-13 | 2019-08-28 | Sbi Pharmaceuticals Co Ltd | Immune tolerance inducer |
-
2019
- 2019-01-16 CN CN201980020068.7A patent/CN112074298B/en active Active
- 2019-01-16 BR BR112020014610A patent/BR112020014610A8/en unknown
- 2019-01-16 AU AU2019209502A patent/AU2019209502B2/en active Active
- 2019-01-16 KR KR1020207023570A patent/KR102492240B1/en active Active
- 2019-01-16 EP EP19700520.0A patent/EP3740242B8/en active Active
- 2019-01-16 US US16/963,107 patent/US12290535B2/en active Active
- 2019-01-16 JP JP2020539755A patent/JP7566629B2/en active Active
- 2019-01-16 CA CA3088710A patent/CA3088710C/en active Active
- 2019-01-16 ES ES19700520T patent/ES3037359T3/en active Active
- 2019-01-16 WO PCT/EP2019/051055 patent/WO2019141731A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| EP3740242B1 (en) | 2025-06-18 |
| CA3088710A1 (en) | 2019-07-25 |
| EP3740242B8 (en) | 2025-07-23 |
| KR20200109352A (en) | 2020-09-22 |
| BR112020014610A8 (en) | 2021-04-06 |
| CN112074298A (en) | 2020-12-11 |
| JP7566629B2 (en) | 2024-10-15 |
| US12290535B2 (en) | 2025-05-06 |
| CA3088710C (en) | 2023-12-12 |
| EP3740242A1 (en) | 2020-11-25 |
| AU2019209502B2 (en) | 2022-05-12 |
| AU2019209502A1 (en) | 2020-07-23 |
| CN112074298B (en) | 2025-05-09 |
| KR102492240B1 (en) | 2023-01-27 |
| JP2021511321A (en) | 2021-05-06 |
| WO2019141731A1 (en) | 2019-07-25 |
| BR112020014610A2 (en) | 2020-12-08 |
| ES3037359T3 (en) | 2025-10-01 |
| US20210047620A1 (en) | 2021-02-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3740242C0 (en) | LANGERIN+ CELL TARGETING | |
| EP3802802A4 (en) | CELL THERAPY | |
| EP3780136A4 (en) | CELL | |
| EP3805270A4 (en) | IMPROVED ANTI-CD19 CAR-T CELL | |
| EP3812254C0 (en) | BATTERY ARRANGEMENT | |
| EP3630939A4 (en) | CELL COLONIES SELECTION SYSTEM | |
| EP4057310A4 (en) | ELECTROLYTE SOLUTION | |
| EP3845661A4 (en) | PYRROLYSYL-ARNT SYNTHETASE | |
| HUE057249T2 (en) | BATTERY | |
| EP3824649A4 (en) | POLLUTION-PROOF MICROPHONE ARRANGEMENT | |
| HUE069188T2 (en) | Battery | |
| MA55905A (en) | IMMUNOTHERAPIES TARGETING CLL -1 | |
| EP3829776A4 (en) | FLOTATION CELL | |
| EP3925330A4 (en) | MULTIPLE CELL LOCATION | |
| MA55910A (en) | IMMUNOTHERAPIES TARGETING CD123 | |
| EP3977042C0 (en) | SHAPED CHARGE | |
| EP3890045A4 (en) | ELECTROCHEMICAL CELL | |
| PL3880802T3 (en) | Improved way to produce T cells | |
| EP3896227A4 (en) | DEFENSE STRUCTURE | |
| EP3829773A4 (en) | FLOTATION CELL | |
| EP4018164C0 (en) | ELECTRODE ARRANGEMENT | |
| EP3829774A4 (en) | FLOTATION CELL | |
| EP4031236A4 (en) | NEURO-STIMULATOR ARRANGEMENTS | |
| EP3970211C0 (en) | SUBMARINE | |
| EP4058414A4 (en) | FITTING ARRANGEMENT |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: UNKNOWN |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
| 17P | Request for examination filed |
Effective date: 20200727 |
|
| AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
| AX | Request for extension of the european patent |
Extension state: BA ME |
|
| RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: HUMBOLDT-UNIVERSITAET ZU BERLIN Owner name: MAX-PLANCK-GESELLSCHAFT ZUR FOERDERUNG DER WISSENSCHAFTEN E.V. |
|
| DAV | Request for validation of the european patent (deleted) | ||
| DAX | Request for extension of the european patent (deleted) | ||
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
| 17Q | First examination report despatched |
Effective date: 20210713 |
|
| GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: GRANT OF PATENT IS INTENDED |
|
| GRAJ | Information related to disapproval of communication of intention to grant by the applicant or resumption of examination proceedings by the epo deleted |
Free format text: ORIGINAL CODE: EPIDOSDIGR1 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
| RIC1 | Information provided on ipc code assigned before grant |
Ipc: C12N 5/0784 20100101ALI20241010BHEP Ipc: A61K 39/00 20060101ALI20241010BHEP Ipc: G01N 33/543 20060101ALI20241010BHEP Ipc: G01N 33/50 20060101ALI20241010BHEP Ipc: A61K 47/69 20170101ALI20241010BHEP Ipc: A61K 47/54 20170101AFI20241010BHEP |
|
| GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: GRANT OF PATENT IS INTENDED |
|
| INTG | Intention to grant announced |
Effective date: 20241030 |
|
| GRAJ | Information related to disapproval of communication of intention to grant by the applicant or resumption of examination proceedings by the epo deleted |
Free format text: ORIGINAL CODE: EPIDOSDIGR1 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
| INTC | Intention to grant announced (deleted) | ||
| INTG | Intention to grant announced |
Effective date: 20241125 |
|
| GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: GRANT OF PATENT IS INTENDED |
|
| INTC | Intention to grant announced (deleted) | ||
| INTG | Intention to grant announced |
Effective date: 20250115 |
|
| GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
| GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE PATENT HAS BEEN GRANTED |
|
| AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
| REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D |
|
| REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP Ref country code: CH Ref legal event code: PK Free format text: BERICHTIGUNG B8 |
|
| REG | Reference to a national code |
Ref country code: DE Ref legal event code: R096 Ref document number: 602019071206 Country of ref document: DE |
|
| REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP Ref country code: CH Ref legal event code: PK Free format text: BERICHTIGUNG B8 |
|
| REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
| U01 | Request for unitary effect filed |
Effective date: 20250623 |
|
| U07 | Unitary effect registered |
Designated state(s): AT BE BG DE DK EE FI FR IT LT LU LV MT NL PT RO SE SI Effective date: 20250701 |
|
| REG | Reference to a national code |
Ref country code: ES Ref legal event code: FG2A Ref document number: 3037359 Country of ref document: ES Kind code of ref document: T3 Effective date: 20251001 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20250919 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: HR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20250618 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: RS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20250918 |